fulvestrant has been researched along with lucitanib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agrapart, V; Andre, F; Bachelot, T; Bossard, CJ; Campone, M; Dubois, F; Guigal-Stephan, N; Lockhart, B; Pallis, A; Penault-Llorca, F; Pierrat, MJ; Poirot, C; Xuereb, L | 1 |
| Arteaga, CL; Balko, JM; Bardia, A; Bauer, JA; Behdad, A; Cristofanilli, M; Croessmann, S; Cruz, MR; Dugger, TC; Ericsson, PG; Formisano, L; Guerrero-Zotano, AL; Guo, Y; Hanker, AB; He, W; Jansen, VM; Lanman, RB; Lee, KM; Lu, Y; Mayer, IA; Miller, M; Nagy, RJ; Nixon, MJ; O'Shaughnessy, J; Sanders, ME; Schwarz, LJ; Servetto, A; Shyr, Y; Solovieff, N; Su, F; Sudhan, DR | 1 |
1 trial(s) available for fulvestrant and lucitanib
| Article | Year |
|---|---|
A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Fulvestrant; Humans; Maximum Tolerated Dose; Middle Aged; Naphthalenes; Neoplasm Metastasis; Postmenopause; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Estrogen | 2019 |
1 other study(ies) available for fulvestrant and lucitanib
| Article | Year |
|---|---|
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; MCF-7 Cells; Mice; Mutation; Naphthalenes; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Quinolines; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |